Signals, Powered By EquityPandit
Zydus Cadila has received final approval to market Candesartan Cilexetil and Hydrochlorothiazide tablets formulations, from the US health regulator. It is used for treating high blood pressure.
In a BSE filing Cadila Healthcare stated, “The approval by the US Food and Drug Administration (USFDA) is for multiple Candesartan Cilexetil and hydrochlorothiazide tablets of 16 mg/12.5 mg, 32 mg/12.5 mg and 32 mg/25 mg.”
Further it stated that, the product will be manufactured at the group’s formulations manufacturing facility at Moraiya, in Ahmedabad.
